Aclarion Q1 2023 Earnings Report

Aclarion EPS Results

• Actual EPS: -$21,708.00
• Consensus EPS: N/A
• Beat/Miss: N/A
• One Year Ago EPS: N/A

Aclarion Revenue Results

• Actual Revenue: $0.03 million
• Expected Revenue: N/A
• Beat/Miss: N/A
• YoY Revenue Growth: N/A

Aclarion Announcement Details

• Quarter: Q1 2023
• Date: 7/3/2023
• Time: N/A
• Conference Call Date: Sunday, July 2, 2023
• Conference Call Time: 6:00PM ET

Aclarion (NASDAQ:ACON) (NASDAQ: ACON) is a medical technology company focused on the development and commercialization of advanced endoscopic solutions for the diagnosis and treatment of ear disorders. Founded in 2012 and headquartered in Irvine, California, Aclarion leverages proprietary optics and digital imaging technologies to create devices that enhance visualization and precision during otologic procedures. The company’s mission is to address unmet clinical needs in ear health by delivering minimally invasive, patient-friendly tools that improve outcomes for both clinicians and patients.

The company’s flagship offering, the Aclarion Endoscopic Platform, integrates high-resolution optics with ergonomically designed instruments to facilitate procedures such as tympanoplasty, cholesteatoma removal and Eustachian tube interventions. Complementing its hardware portfolio, Aclarion is developing software modules that provide real-time image enhancement and procedural guidance, with the goal of reducing operative time and improving surgical accuracy. Early studies and physician feedback have underscored the platform’s potential to expand the adoption of endoscopic ear surgery in hospital and ambulatory care settings.

Aclarion maintains a global footprint, with commercial and regulatory activities underway in the United States, Europe and select markets in Asia Pacific. The company has engaged with leading distribution partners to support product launches and training initiatives, and is actively pursuing FDA clearances and CE marks for additional indications. This geographic expansion strategy is designed to build a robust clinical evidence base and establish Aclarion’s footprint among ENT specialists worldwide.

Under the leadership of Chief Executive Officer John Marshall—an industry veteran with over two decades of experience in medical device innovation—Aclarion is guided by a management team combining expertise in otology, engineering and regulatory affairs. The board of directors includes prominent surgeons and life sciences executives who contribute strategic insight as the company advances its pipeline and prepares for broader market entry. Aclarion continues to invest in research collaborations and clinical studies to reinforce its position at the forefront of endoscopic ear care.